Waldron Private Wealth LLC Purchases 95 Shares of Amgen Inc. (NASDAQ:AMGN)

Waldron Private Wealth LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,343 shares of the medical research company’s stock after acquiring an additional 95 shares during the quarter. Waldron Private Wealth LLC’s holdings in Amgen were worth $5,588,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in AMGN. Strategic Financial Concepts LLC bought a new stake in Amgen during the second quarter valued at $26,000. Hershey Financial Advisers LLC bought a new position in Amgen in the 2nd quarter valued at about $30,000. nVerses Capital LLC purchased a new position in shares of Amgen during the second quarter valued at approximately $31,000. Bbjs Financial Advisors LLC purchased a new stake in Amgen in the 2nd quarter valued at about $33,000. Finally, Matrix Trust Co purchased a new position in shares of Amgen in the 3rd quarter worth approximately $36,000. 76.50% of the stock is owned by institutional investors.

Amgen Trading Up 0.9 %

AMGN stock traded up $2.74 during midday trading on Tuesday, hitting $319.48. The company had a trading volume of 901,481 shares, compared to its average volume of 2,435,656. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. Amgen Inc. has a 52 week low of $249.70 and a 52 week high of $346.85. The stock has a market cap of $171.38 billion, a price-to-earnings ratio of 45.06, a PEG ratio of 2.86 and a beta of 0.61. The stock’s 50 day moving average price is $326.00 and its 200 day moving average price is $312.76.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The firm had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. Amgen’s revenue was up 20.1% on a year-over-year basis. During the same period last year, the business earned $5.00 EPS. As a group, equities research analysts expect that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were given a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.82%. Amgen’s dividend payout ratio is currently 128.57%.

Analysts Set New Price Targets

A number of brokerages recently commented on AMGN. Bank of America increased their price target on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 target price (up from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Morgan Stanley reduced their price target on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research report on Thursday, July 11th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $362.00 price objective on shares of Amgen in a research report on Thursday, September 26th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $305.00 price target (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $332.55.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.